The Priority Review

Category

Approvals

Decisions by the FDA and other regulators on new drugs, biologics and devices.

58 stories · page 1 of 5

Stories

  1. FDA approves giredestrant with everolimus for ESR1-mutated breast cancer

    On November 16, 2026 the FDA approved giredestrant (Wilserdly) in combination with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. The approval includes the FoundationOne Liquid CDx assay as a companion diagnostic to identify ESR1 mutations.

  2. FDA approves durvalumab combination for cisplatin-ineligible muscle invasive bladder cancer

    The FDA approved durvalumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer in adults who are ineligible for or refused cisplatin-based chemotherapy. In VOLGA, the hazard ratio for event-free survival was 0.51 against radical cystectomy alone.

  3. FDA approves Gazyva for adults with primary membranous nephropathy at risk of progression

    The FDA approved Gazyva (obinutuzumab) for adults with primary membranous nephropathy, with complete remission of proteinuria at week 104 in 36% versus 6% on tacrolimus in MAJESTY. The FDA said it is the first drug approved specifically for these adults.

  4. FDA approves first drug to treat adults with primary membranous nephropathy

    The FDA approved Gazyva (obinutuzumab) injection for adults with primary membranous nephropathy at risk of disease progression to induce remission of proteinuria. In the MAJESTY Phase 3 study, 36% of patients achieved complete remission at week 104 versus 6% with tacrolimus.

  5. FDA approves durvalumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer

    On November 13, 2026, the FDA approved durvalumab (Imfinzi, AstraZeneca) in combination with enfortumab vedotin-ejfv as neoadjuvant treatment followed by single-agent durvalumab as adjuvant therapy after radical cystectomy for adult patients with muscle invasive bladder cancer who are ineligible for or have refused cisplatin-based chemotherapy. The approval was granted under priority review and six weeks ahead of the FDA goal date.

  6. EMA recommends approval of seven new medicines at CHMP meeting

    The Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization for Aumseqa, Baxfendy, Zybrivo, Garzulys, Donrafylix, Fondaparinux sodium Evumed, and Ruxolitinib Krka. The recommendations cover treatments for non-small cell lung cancer, hypertension, non-squamous non-small cell lung cancer, diabetes, venous thromboembolism, and myelofibrosis, among others.

  7. CHMP adopts positive opinion on Zybrivo for non-squamous NSCLC

    On 12 November 2026 the CHMP recommended granting a marketing authorization for Zybrivo, a sintilimab-based therapy, for first-line treatment of adult non-squamous non-small cell lung cancer. The recommendation follows a randomised, multicentre, double-blind, placebo-controlled study showing improved progression-free survival when sintilimab is combined with chemotherapy.

  8. CHMP recommends marketing authorization for Ruxolitinib Krka

    On 12 November 2026 the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for Ruxolitinib Krka, intended for the treatment of myelofibrosis, polycythaemia vera and graft-versus-host disease. The generic will be available as 5 mg, 10 mg, 15 mg and 20 mg tablets.

  9. CHMP adopts positive opinion on Fondaparinux sodium Evumed

    On 12 November 2026 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a marketing authorization for Fondaparinux sodium Evumed, a generic of Arixtra. The product is intended for prevention of venous thromboembolic events in adults undergoing major orthopaedic or abdominal surgery, immobilised patients, and for treatment of unstable angina, myocardial infarction, superficial-vein thrombosis, deep-vein thrombosis and pulmonary embolism.

  10. CHMP adopts positive opinion on Donrafylix

    On 12 November 2026 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for Donrafylix, a biosimilar insulin aspart intended for the treatment of diabetes mellitus. The applicant is Kuraci BV and Donrafylix will be available as a 100 units/ml solution for injection.

  11. CHMP adopts positive opinion on Baxfendy

    The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on 12 November 2026, recommending marketing authorization for Baxfendy, a baxdrostat tablet for uncontrolled hypertension. The opinion was issued by the EMA for AstraZeneca AB.

  12. CHMP adopts positive opinion on Aumseqa

    The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a marketing authorization for Aumseqa, a 55 mg film-coated tablet intended for first-line treatment of adult patients with advanced NSCLC harbouring EGFR exon 19 deletions or L858R mutations, and for treatment of EGFR T790M mutation-positive NSCLC. The applicant for the medicinal product is SFL Pharmaceuticals Deutschland GmbH.